5 articles
JPMorgan projects rising Indian outbound M&A to secure supply chains, exemplified by Sun Pharma's $11.75 billion Organon deal. Total M&A hit $100 billion in H1 2026, driven by needs for critical miner
Sun Pharmaceutical Industries agreed to acquire Organon for $11.75 billion, gaining access to its biosimilars portfolio and becoming a top-three global women's health company.
India's Sun Pharmaceutical Industries agreed to acquire U.S. drugmaker Organon & Co in an all-cash deal valued at approximately $11.75 billion. The transaction grants Sun Pharma full ownership of the
Organo has established a new subsidiary in India to target the country's growing water treatment market. This expansion supports the company's strategy to meet increasing regional demand for purificat
Organo Corp reported a decline in functional products sales for the first nine months of the fiscal year, despite rising water treatment chemical sales.
ChemBrief